Cannabidiol is a Small Molecule owned by Zynerba Pharmaceuticals, and is involved in 16 clinical trials, of which 12 were completed, 2 are ongoing, and 2 are planned.
Cannabidiol is a CB1 and CB2 receptor agonist. Cannabinoid receptors consists of two types of receptors (cannabinoid receptor type 1 (CB1) and type II (CB2)). The drug candidate mimics the action of endocannabinoids that are augmented by cannabinoid receptors and helps in regulating the transmission of impulses from one nerve to another. The drug candidate modulates the anti-epileptic effects of cannabinoids due to activation of these receptors release of endocannabinoids which might inhibit the release of further excitatory neurotransmitters. The drug candidate also inhibits FAAH and increases 2-AG and anandamide concentrations, which facilitates the release of neurotransmitters.
CBD is a agonist at the human 5-HT1a receptor. Cannabinoids act as ligands conferring their ability to modulate a receptor’s behavior and consequently their downstream biological pathways. Cannabinoids also have the ability to increase adenosine signaling by preventing its clearance through the adenosine re-uptake transporter. The release of adenosine is an endogenous mechanism of immunosuppression evoked during cellular stress and inflammation. The drug candidate by agonizing CB1, CB2 and 5HT1A regulates the levels of adenosine and ameliorates the disease condition.
It acts as a competitive antagonist at the G-protein coupled receptor, GPR55, inhibiting binding of a membrane phospholipid, lysophosphatidylinositol (LPI).The drug candidate by opposing LPI action blocks LPI- mediated increases in presynaptic Ca2+ and vesicular release, thus reducing excitability at axon terminals.
The revenue for Cannabidiol is expected to reach a total of $1.2bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Cannabidiol NPV Report.
Cannabidiol is currently owned by Zynerba Pharmaceuticals.
Cannabidiol (ZYN-002) is under development for the treatment of neuropsychiatric disorders including developmental epileptic encephalopathy in children and adolescents, Fragile X syndrome in children and adolescents, adult refractory focal seizures, pediatric autism spectrum disorder (ASD) (pervasive developmental disorder) and 22q11.2 deletion syndrome. It is applied transdermally as a gel. The drug candidate targets cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptors and also fatty acid amide hydrolase. It was also under development for the treatment of rheumatoid arthritis and knee pain due to osteoarthritis. It was under development for drug and alcohol addiction.
Zynerba Pharmaceuticals Overview
Zynerba Pharmaceuticals, formerly AllTranz, is a developer of next-generation synthetic cannabinoid therapeutics. The company produce transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. The company provides pipeline product candidates includes ZYN002. Its ZYN002 is a synthetic CBD, a non- cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery. Zynerba Pharmaceuticals’s ZYN002 is administered as a transdermal gel to children and adolescents with autism spectrum disorder. The company’s pipeline candidates target various indications which include refractory epileptic focal, fragile x syndrome, developmental and epileptic encephalopathies and autism spectrum disorder. Zynerba Pharmaceuticals is headquartered in Devon, Pennsylvania, the US.
The operating loss of the company was US$36.8 million in FY2021, compared to an operating loss of US$52.1 million in FY2020. The net loss of the company was US$37.3 million in FY2021, compared to a net loss of US$51.3 million in FY2020.
Quick View – Cannabidiol
|Highest Development Stage|